Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2021; 27(22): 3037-3049
Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.3037
Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
Yun Zhang, Zi-Xing Huang, Bin Song
Yun Zhang, Zi-Xing Huang, Bin Song, Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zhang Y and Song B designed the research; Zhang Y and Huang ZX conducted literature search and analysis; Huang ZX and Song B provided material support and revised and proofread the paper; Huang ZX and Song B contributed equally to this work.
Conflict-of-interest statement: The authors have nothing to disclose regarding this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Bin Song, MD, Chief Doctor, Director, Professor, Department of Radiology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China.
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: February 25, 2021
Revised: March 8, 2021
Accepted: April 26, 2021
Article in press: April 26, 2021
Published online: June 14, 2021
Core Tip

Core Tip: The timely and accurate evaluation of tumor response in patients with pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) is of great significance to increase the probability of tumor R0 resection and prolong survival. Ultrasound and conventional computed tomography imaging features show limited roles in the evaluation of NAT response for PDAC. Novel imaging biomarkers extracted from functional imaging technologies show promise in providing further important information for the assessment of tumor resectability and survival prediction. We reviewed the application and value of NAT in PDAC, as well as the advantages, limitations, and future development directions of current imaging techniques in tumor response assessment of PDAC after NAT in this article.